Loading…
CELU
Celularity Inc
NASDAQ· Healthcare· Biotechnology· CUSIP 151190204
$1.58-24.76%Price as of Aug 29, 18:39 UTC · updated once a day, after the close
Key metrics
- Market cap
- $45.73M
- P/E
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- —
- Payout
- —
- EPS
- -$3.59
- ROE
- —
- Profit margin
- 0.00%
- Revenue growth
- -77.40%
- Beta
- 0.54
- 52-week high
- $3.15
- 52-week low
- $0.56
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -98.0% over 5Y.
today you would have $19.49▼ -98.1%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 7 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Year-end price | $1.11 | $2.08 | $2.47 | $12.90 | $51.20 | $110.00 | $99.50 | |
| P/E | — | — | — | — | 13.6x | — | — | 99.5x |
| P/S | 7.0x | 1.2x | 0.9x | 2.1x | 11.8x | 33.1x | 14.3x | — |
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| HOWLWerewolf Therapeutics, Inc. | $0.94 | — | 2.8x | — | -119.86% | $45.84M |
| QTIQt Imaging Holdings Inc | $3.09 | — | 19.0x | — | -2125.30% | $45.23M |
| LITSLite Strategy, Inc. | $1.36 | — | 0.8x | — | -159.26% | $46.27M |
| MGXMetagenomi Therapeutics, Inc. | $1.19 |
About the company
Celularity Inc., a cellular and regenerative medicine company, focuses on addressing aging-related disease using novel therapies. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. It develops off-the-shelf placental-derived allogeneic cell therapy product candidates, including mesenchymal-like adherent stromal cells for diabetic foot ulcer and Crohn's disease. Its therapeutic programs include PDA-001 for the treatment of autoimmune (Crohn's) and degenerative disease; and PDA-002 for treating multiple sclerosis, rheumatoid arthritis, stroke, and diabetic peripheral neuropathy. The company also produces, sells, and licenses products used in surgical and wound care markets, such as Biovance, Biovance 3L, Rebound, Interfyl, and Centaflex; and collects, processes, and stores umbilical cord and placental blood and tissue after full-term pregnancies under the LifebankUSA brand. Celularity Inc. has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. Celularity Inc. was founded in 1998 and is headquartered in Florham Park, New Jersey.
- 115
- Florham Park, United States
Company description provided by Yahoo Finance.